Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SYRE

Spyre Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SYRE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2023)$-49.12

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 04:30 UTC.

What Spyre Therapeutics, Inc. does

Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies to treat inflammatory bowel disease and rheumatic diseases. The company's pipeline includes extended half-life antibodies targeting four distinct pathways in development as individual treatments and fixed-dose combinations. Spyre's antibodies are engineered with modifications to increase how long they remain in the body, potentially enabling dosing several times per year instead of more frequently.

Summarized from Spyre Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2023)$-49.12

Revenue, margins & earnings

FY2021: net loss $66M on revenue $19M$19MFY2021FY2022: net loss $84M on revenue $2M$2MFY2022FY2023: net loss $339M on revenue $886,000$886,000FY2023
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02Chief Financial OfficerSale-2,100$193.0K
  • 2026-10-02Chief Executive OfficerSale-3,989$368.2K
  • 2026-10-02Chief Executive OfficerSale-100$9.4K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Spyre Therapeutics, Inc. do?

Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies to treat inflammatory bowel disease and rheumatic diseases.

When did SYRE last file with the SEC?

Spyre Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 04:30 UTC. This page is also available as JSON at /api/data?ticker=SYRE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SYRE and 5,000+ tickers.

Create a free account — keep SYRE
For your agent
GET /api/data?ticker=SYRE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt